80 related articles for article (PubMed ID: 15148832)
21. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.
Ebert O; Harbaran S; Shinozaki K; Woo SL
Cancer Gene Ther; 2005 Apr; 12(4):350-8. PubMed ID: 15565179
[TBL] [Abstract][Full Text] [Related]
22. A novel HSV-1 virus, JS1/34.5-/47-, purges contaminating breast cancer cells from bone marrow.
Hu JC; Booth MJ; Tripuraneni G; Davies D; Zaidi SA; Tamburo de Bella M; Slade MJ; Marley SB; Gordon MY; Coffin RS; Coombes RC; Kamalati T
Clin Cancer Res; 2006 Nov; 12(22):6853-62. PubMed ID: 17121907
[TBL] [Abstract][Full Text] [Related]
23. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
24. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells.
Taneja S; MacGregor J; Markus S; Ha S; Mohr I
Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8804-8. PubMed ID: 11438715
[TBL] [Abstract][Full Text] [Related]
25. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus.
Fu X; Tao L; Cai R; Prigge J; Zhang X
Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513
[TBL] [Abstract][Full Text] [Related]
26. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases.
Nomura N; Kasuya H; Watanabe I; Shikano T; Shirota T; Misawa M; Sugimoto H; Kanazumi N; Nomoto S; Takeda S; Nakao A
Cancer Chemother Pharmacol; 2009 Jan; 63(2):321-30. PubMed ID: 18575868
[TBL] [Abstract][Full Text] [Related]
27. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
[TBL] [Abstract][Full Text] [Related]
28. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
Fu X; Tao L; Zhang X
Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
[TBL] [Abstract][Full Text] [Related]
29. Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor.
Ishihara M; Seo N; Mitsui J; Muraoka D; Tanaka M; Mineno J; Ikeda H; Shiku H
PLoS One; 2014; 9(8):e104669. PubMed ID: 25105508
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
Todo T; Rabkin SD; Martuza RL
Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
[TBL] [Abstract][Full Text] [Related]
31. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
Li H; Dutuor A; Fu X; Zhang X
J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
[TBL] [Abstract][Full Text] [Related]
32. [Oncolytic virus therapy for malignant brain tumors].
Ino Y; Todo T
Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
[TBL] [Abstract][Full Text] [Related]
33. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms.
Nakamori M; Fu X; Meng F; Jin A; Tao L; Bast RC; Zhang X
Clin Cancer Res; 2003 Jul; 9(7):2727-33. PubMed ID: 12855653
[TBL] [Abstract][Full Text] [Related]
34. Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses.
Sugiura S; Goshima F; Takakuwa H; Sata T; Nakashima T; Nishiyama Y
Otolaryngol Head Neck Surg; 2004 Apr; 130(4):470-8. PubMed ID: 15100647
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
Chung YS; Miyatake S; Miyamoto A; Miyamoto Y; Dohi T; Tanigawa N
Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters.
Nakano K; Todo T; Chijiiwa K; Tanaka M
Mol Ther; 2001 Apr; 3(4):431-7. PubMed ID: 11319903
[TBL] [Abstract][Full Text] [Related]
37. [Progess on research of herpes simplex virus type 1 mutants for cancer therapy].
Long Y; Mi Y; Li Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Dec; 25(6):1446-9. PubMed ID: 19166228
[TBL] [Abstract][Full Text] [Related]
38. A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation.
Samoto K; Perng GC; Ehtesham M; Liu Y; Wechsler SL; Nesburn AB; Black KL; Yu JS
Cancer Gene Ther; 2001 Apr; 8(4):269-77. PubMed ID: 11393279
[TBL] [Abstract][Full Text] [Related]
39. Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials.
Eissa IR; Naoe Y; Bustos-Villalobos I; Ichinose T; Tanaka M; Zhiwen W; Mukoyama N; Morimoto T; Miyajima N; Hitoki H; Sumigama S; Aleksic B; Kodera Y; Kasuya H
Front Oncol; 2017; 7():149. PubMed ID: 28770166
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma.
Takano G; Esaki S; Goshima F; Enomoto A; Hatano Y; Ozaki H; Watanabe T; Sato Y; Kawakita D; Murakami S; Murata T; Nishiyama Y; Iwasaki S; Kimura H
Mol Ther Oncolytics; 2021 Mar; 20():220-227. PubMed ID: 33665360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
